Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)
The PMCPA twisted the knife in its latest ruling against Otsuka, accusing the company of an unacceptable failure to give a full and frank disclosure.
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Otsuka to Terminate Development of AVP-786
Otsuka is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.
After the FDA forced Rexulti depression ads off the air, Lundbeck reported a flattening of prescriptions that is rebounding now promotion has resumed.
Enforcement Report - Week of May 1, 2024
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry
FDA clears Otsuka, Click's prescription app for depression
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms